How are the results of the Oncotype DX assay reported?
The results of the Oncotype DX assay are presented as a Recurrence Score result (0-100). In addition to the individual test results, an overview of the clinical validation study is provided which correlates Recurrence Score result with likelihood of distant recurrence at 10 years for node-negative, ER-positive patients treated with tamoxifen. The node-negative report now includes results from the NSABP B-20 study of chemotherapy benefit according to the Recurrence Score result for node-negative, estrogen-receptor-positive patients treated with tamoxifen. The node-positive report includes results from the SWOG 8814 study of prognosis and chemotherapy benefit for node-positive, hormone-receptor-positive post-menopausal patients treated with tamoxifen. The final page of both reports displays the ER (Estrogen Receptor), PR (Progesterone Receptor) and HER2 Scores, based on the assessment of the expression of each of these genes. The report form itself is delivered via fax, overnight mail or
